
With the consequences of FCPA noncompliance ranging from “huge” to “catastrophic,” compliance should be top-of-mind for U.S. companies doing business with third-party intermediaries and subsidiaries overseas. In a conversation with Mimesis Law’s Lee Pacchia, Foley Partner David Simon discusses how companies should approach investigations to go beyond the “who,” “what,” “where,” and “when” to address the “why,” while 1) meeting U.S. government expectations for the investigation, 2) maintaining control of the investigation, and 3) reining in “scope creep.”
Author(s)
Related Insights
July 16, 2025
Health Care Law Today Podcast
Episode 36: Let’s Talk Compliance: The Risks and Pitfalls of Health Care Supply Chain Compliance
July 15, 2025
Innovative Technology Insights
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…
July 15, 2025
Health Care Law Today
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…